180 related articles for article (PubMed ID: 33812852)
1. Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD.
Mahler DA; Halpin DMG
Chest; 2021 Aug; 160(2):491-498. PubMed ID: 33812852
[TBL] [Abstract][Full Text] [Related]
2. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease.
Mahler DA
Ann Am Thorac Soc; 2017 Jul; 14(7):1103-1107. PubMed ID: 28481631
[TBL] [Abstract][Full Text] [Related]
3. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease.
Mahler DA
Respir Med; 2020 Jan; 161():105857. PubMed ID: 32056720
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.
Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB
Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948
[TBL] [Abstract][Full Text] [Related]
5. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
[TBL] [Abstract][Full Text] [Related]
6. Consideration and Assessment of Patient Factors When Selecting an Inhaled Delivery System in COPD.
Mahler DA; Halpin DMG
Chest; 2024 Feb; 165(2):323-332. PubMed ID: 37977266
[TBL] [Abstract][Full Text] [Related]
7. Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.
Price DB; Yang S; Ming SWY; Hardjojo A; Cabrera C; Papaioannou AI; Loukides S; Kritikos V; Bosnic-Anticevich SZ; Carter V; Dorinsky PM
Int J Chron Obstruct Pulmon Dis; 2018; 13():3937-3946. PubMed ID: 30587952
[TBL] [Abstract][Full Text] [Related]
8. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
Ghosh S; Ohar JA; Drummond MB
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581
[TBL] [Abstract][Full Text] [Related]
9. Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD.
Jõgi R; Mattila L; Vahteristo M; Takala A; Lähelmä S; Vartiainen VA; Lindqvist A
Int J Chron Obstruct Pulmon Dis; 2021; 16():1193-1201. PubMed ID: 33958863
[TBL] [Abstract][Full Text] [Related]
10. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
11. Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD.
Chetta A; Yorgancioglu A; Scuri M; Barile S; Guastalla D; Dekhuijzen PNR
BMC Pulm Med; 2021 Feb; 21(1):65. PubMed ID: 33632183
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
Harb HS; Laz NI; Rabea H; Abdelrahim MEA
Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
15. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
16. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea.
Moon JY; Kim SH; Kim Y; Lee H; Rhee CK; Ra SW; Lee CY; Park JH; Park YB; Yoo KH
Pulm Pharmacol Ther; 2024 Jun; 85():102298. PubMed ID: 38604404
[TBL] [Abstract][Full Text] [Related]
18. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
19. Ability of using different dry powder inhalers during COPD exacerbations.
Papaioannou AI; Herodotou Y; Tomos I; Apollonatou V; Verykokou G; Papathanasiou E; Manali ED; Loukides S; Papiris SA
Pulm Pharmacol Ther; 2018 Feb; 48():211-216. PubMed ID: 29277688
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
